FindTrial
Sign In

Effect of Celevida among Overweight/Obese Adults with Type 2 Diabetes

Effect of Celevida on 24hr Glycemic Response in overweight/obese Adults with Type 2 Diabetes: a 24-week randomized controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/05/014034
Enrollment
60
Registered
2018-05-22
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Obese Type 2 Diabetes Mellitus

Interventions

Intervention1: Celevida: Celevida dietary supplement will be given to the patients twice a day for 6 months along with standard care of process for diabetes Control Intervention1: Standard Care: Patie

Sponsors

Madras Diabetes Research Foundation
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Overweight/ obese diabetic patients (Asian Indian specific cut offs) 2.Age group 30 to 65 yrs both males and females 3.Participants with type 2 diabetes and HbA1c from 7% to 10% 4.Participantâ??s duration of diabetes to be at least one year. 5.Participants on OHA with stable doses for at least 3 months 6.Willing to follow study protocol 7.Willing to give informed consent

Exclusion criteria

Exclusion criteria: 1.Non-diabetes 2.Individual on insulin injections 3.Participants who have fluctuations in glucose levels and those with alterations of dosages of OHA in last 3 months. 4.Any acute infections like viral fever, typhoid, cold, diarrhea, constipation last 1 month 5.Person with complications such as respiratory disorders, cancer or heart attack and stroke 6.Patient has history of malignancy in the past 1 year. 7.Patients having any eating disorder or Lactogen intolerance 8.History of hypoglycaemia in last 3 months 9.Patient taking any herbal/Ayurvedic/Traditional preparation that could profoundly affect blood glucose 10.Pregnant and lactating Women 11.Plans to relocate in the next 2 years. 12.Planning longer duration of travel out of town

Design outcomes

Primary

MeasureTime frame
Study result will help evaluate the long term health benefits of Celevida on 24hr glycemic response in the management of type 2 diabetes.Timepoint: 6 months—

Secondary

MeasureTime frame
Assessment of the effect of celevida on fasting and post prandial blood glucose, HbA1c, body weight, lipid profile and blood pressure.Timepoint: 6 months—

Countries

India

Contacts

Public ContactMrs Sudha Vasudevan

Madras Diabetes Research Foundation

s2r_7@mdrf.in04443968487

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026